925results about How to "Shorten the progress" patented technology

The present invention relates to methods of treating and preventing Alzheimer's Disease or other tauopathies in a subject by administering a tau protein, its immunogenic epitopes, or antibodies recognizing the tau protein or its immunogenic epitopes under conditions effective to treat or prevent Alzheimer's Disease of other tauopathies. Also disclosed are methods of promoting clearance of aggregates from the brain of the subject and of slowing progression of tangle-related behavioral phenotype in a subject.

A method of treating age-related macular degeneration in an eye is described, comprising contacting the eye with a therapeutic amount of a prostaglandin F2alpha derivative. The preferred prostaglandin F2alpha derivative is latanoprost, and the preferred dosage is between about 1.5 mug and about 4.5 mug per day per eye.

The present invention relates to methods and compositions for treating, preventing, and diagnosing Alzheimer's Disease or other tauopathies in a subject by administering an immunogenic tau peptide or an antibody recognizing the immunogenic tau epitope under conditions effective to treat, prevent, or diagnose Alzheimer's Disease or other tauopathies. Also disclosed are methods of promoting clearance of aggregates from the brain of the subject and of slowing progression of tau-pathology related behavioral phenotype in a subject.

A system and method for sharing and absorbing energy between body parts. In one particular aspect, the system facilitates absorbing energy between members forming a joint such as between articulating bones.

A method and apparatus are disclosed for controlling optical aberrations to alter relative curvature of field by providing ocular apparatuses, systems and methods comprising a predetermined corrective factor to produce at least one substantially corrective stimulus for repositioning peripheral, off-axis, focal points relative to the central, on-axis or axial focal point while maintaining the positioning of the central, on-axis or axial focal point on the retina. The invention will be used to provide continuous, useful clear visual images while simultaneously retarding or abating the progression of myopia or hypermetropia.

The present invention provides methods for inhibiting protein kinases selected from the group consisting of AKT, Checkpoint kinase, Aurora kinase, Pim kinases, and tyrosine kinase using pyrazolo[1,5-a]pyrimidine compounds and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with protein kinases using such compounds.

A method and apparatus are disclosed for controlling optical aberrations to alter relative curvature of field by providing ocular apparatuses, systems and methods comprising a predetermined corrective factor to produce at least one substantially corrective stimulus for repositioning peripheral, off-axis, focal points relative to the central, on-axis or axial focal point while maintaining the positioning of the central, on-axis or axial focal point on the retina. The invention will be used to provide continuous, useful clear visual images while simultaneously retarding or abating the progression of myopia or hypermetropia.

A contact lens (10) for use in controlling or retarding the progression of myopia in an eye has a central optical zone (20) approximating the normal diameter of the pupil of the eye (22) that gives clear central vision at distance for the wearer. An annular peripheral optical zone 24 that is substantially outside the diameter of the pupil is formed around the central optical zone (20) with greater refractive power than that of the central zone (22) so that oblique rays entering the eye through the peripheral optical zone (24) will be brought to focus at a focal plane that is substantially on or anterior to the peripheral region of the retina. Preferably, the rear surface (16) of the lens is shaped to conform to the cornea of the eye and the front surface (18) of the lens (10) is shaped to provide—in conjunction with the rear surface (16)—the desired optical properties of the central and peripheral optical zones. The front surface (18) is also preferably contoured to form a smooth transition (30) between the junction of the central optical zone (20) and the peripheral optical zone (24), with or without designed optical properties such as progressive power.

The present invention comprises compositions, methods, and devices for creating an stimulating an antigen-specific dendritic cell immune response. Devices and methods provide prophylactic and therapeutic immunity to subjects against cancer and infectious agents.

The present invention relates to a method of treatment for slowing the progress of skin aging comprising contacting the skin with an amount effective to slow skin aging of a composition comprising one or more compounds selected from the group consisting of EGF, bFGF, IGF-1, KGF, TGF-β3, TRX, VEGF, TRX, aFGF, FGF-10, copper peptide, acetyl hexapeptide, palmitoyl pentapeptide, CPP, and UDN glycoprotein.

The present invention discloses a media file on-demand method, comprising: the server, upon receiving the media on-demand request from the client, provides the index information in the self-defining media file to the client; the server, upon receiving the playing progress request from said client, according to the requested time in the playing progress request, searches for the starting offset position of the media data corresponding to the requested time in the index information; the server, according to the starting offset position of the media data, reads out the media data corresponding to the requested time in the self-defining media file, and provides the media data to the client. The present invention further discloses a media file on-demand system and apparatus, wherein the index information derived by analyzing the original media file divides the original media file into individual segments according to time, thus the user, upon watching the program and dragging on the progress bar, is enabled to request the data according to the time so as to quickly acquire the media data at the time corresponding to the drag-and-drop position, so the experience of use by the user is enhanced.

The present invention provides a drug for at least one of prevention and treatment of cardiac failure capable of suppressing cardiac depression and the onset of cardiac failure in ventricular remodeling, and a method for screening the drug. The drug for at least one of prevention and treatment of cardiac failure of the present invention contains a compound that inhibits a functional expression of ASK1 protein in a cardiomyocyte as an active ingredient, and a method for screening a drug for at least one of prevention and treatment of cardiac failure of the present invention includes selecting a medicinal component for at least one of prevention and treatment of cardiac failure from a drug candidate compound by using inhibition of a functional expression of ASK1 protein as an indication. As shown in FIG. 1, if ASK1 protein is removed, for example, the ventricle dilation can be attenuated in ventricular remodeling after myocardial infarction, pressure loading, or the like, which makes it possible to prevent and treat cardiac failure.

The present disclosure relates to ophthalmic devices such as ophthalmic lenses. An ophthalmic device may comprise an ophthalmic lens for at least one of slowing, retarding or preventing myopia progression. The ophthalmic lens may comprise a center zone with a negative power for myopic vision correction; and at least one treatment zone surrounding the center zone, the at least one treatment zone having a power profile comprising an ADD power, the at least one treatment zone having a surface shape comprising a portion of a generally toroidal shape, wherein the at least one treatment zone is arranged as to form a continuous surface with the center zone.

Disclosed herein are compositions and methods used to modulate a NH₂-terminal Jun Kinase activity. These compositions and methods can be employed to regulate metabolic disorders associated with, for example, insulin such as diabetes. The reduction in NH₂-terminal Jun Kinase activity can lead to the reduction in weight and improve insulin sensitivity.